Home > Insider Trading > Filing (0001818382-23-000119)

Filing Details

Accession Number:: 0001818382-23-000119
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-08-21 18:07:15
Reporting Period:: 2023-08-17

Accepted Time:: 2023-08-21 18:07:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1818382	Humacyte Inc.	HUMA	Biological Products, (No Disgnostic Substances) (2836)	851763759

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1878024	Ayabudge Llc	2525 East North Carolina Highway 54 Durham NC 27713		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2023-08-17	570,174	$3.68	9,420,562	No	4	S	Direct
Common Stock	Disposition	2023-08-18	626,979	$3.57	8,793,583	No	4	S	Direct
Common Stock	Disposition	2023-08-21	602,443	$3.39	8,191,140	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Between August 17, 2023 and August 21, 2023, the Reporting Person sold 1,799,596 shares of Common Stock. The transactions enabled Mr. Brady W. Dougan, a person controlling the Reporting Person, to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase.
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $4.13. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.50 to $3.75. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.22 to $3.80. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.